Ameriprise Financial Inc. boosted its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 22.4% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 614,721 shares of the medical instruments supplier’s stock after buying an additional 112,693 shares during the period. Ameriprise Financial Inc. owned 1.67% of AngioDynamics worth $10,666,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Bogle Investment Management L P DE raised its stake in shares of AngioDynamics by 204.3% in the fourth quarter. Bogle Investment Management L P DE now owns 212,894 shares of the medical instruments supplier’s stock worth $3,591,000 after buying an additional 142,939 shares during the last quarter. Norges Bank bought a new position in shares of AngioDynamics during the fourth quarter worth approximately $2,699,000. Cigna Investments Inc. New bought a new position in shares of AngioDynamics during the fourth quarter worth approximately $842,000. Thrivent Financial for Lutherans increased its position in shares of AngioDynamics by 350.9% in the fourth quarter. Thrivent Financial for Lutherans now owns 66,600 shares of the medical instruments supplier’s stock valued at $1,123,000 after buying an additional 51,830 shares in the last quarter. Finally, Bowling Portfolio Management LLC purchased a new stake in shares of AngioDynamics during the first quarter valued at approximately $653,000. Hedge funds and other institutional investors own 84.20% of the company’s stock.
Shares of AngioDynamics, Inc. (ANGO) opened at 16.42 on Friday. The firm’s market capitalization is $603.93 million. AngioDynamics, Inc. has a one year low of $12.25 and a one year high of $18.18. The company’s 50 day moving average is $15.64 and its 200-day moving average is $16.34.
AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Thursday, March 30th. The medical instruments supplier reported $0.19 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.04. The company had revenue of $85.60 million during the quarter, compared to the consensus estimate of $88.29 million. AngioDynamics had a negative net margin of 7.31% and a positive return on equity of 5.20%. The firm’s revenue for the quarter was down 2.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.15 earnings per share. Equities analysts expect that AngioDynamics, Inc. will post $0.70 EPS for the current year.
Several analysts have issued reports on the stock. Craig Hallum set a $20.00 target price on shares of AngioDynamics and gave the company a “buy” rating in a research note on Saturday, April 1st. Cantor Fitzgerald reaffirmed a “buy” rating and set a $20.00 price objective on shares of AngioDynamics in a research report on Thursday, March 30th. Canaccord Genuity reissued a “hold” rating and issued a $17.50 price target on shares of AngioDynamics in a research report on Thursday, March 30th. Finally, Zacks Investment Research raised shares of AngioDynamics from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a research note on Wednesday, March 29th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $18.58.
In related news, major shareholder Avista Capital Partners Gp, Ll sold 2,350,000 shares of the stock in a transaction dated Wednesday, April 12th. The shares were sold at an average price of $16.00, for a total transaction of $37,600,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.88% of the stock is currently owned by corporate insiders.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.